

Geraldine Pignot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/135403/publications.pdf>

Version: 2024-02-01

25
papers

750
citations

759233

12
h-index

642732

23
g-index

27
all docs

27
docs citations

27
times ranked

1514
citing authors

#	ARTICLE	IF	CITATIONS
1	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. <i>World Journal of Urology</i> , 2023, 41, 619-625.	2.2	8
2	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e339-e345.	1.9	6
3	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN. <i>Future Oncology</i> , 2022, , .	2.4	0
4	Surgical management in metastatic renal cell carcinoma. <i>Bulletin Du Cancer</i> , 2022, 109, 2S59-2S65.	1.6	0
5	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 577-584.	5.4	19
6	Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. <i>Minerva Urology and Nephrology</i> , 2021, 73, 215-224.	2.5	4
7	Enfortumab vedotin for cisplatin-ineligible urothelial cancer. <i>Lancet Oncology</i> , The, 2021, 22, 748-749.	10.7	1
8	â€œReal-worldâ€ evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 2.e1-2.e9.	1.6	7
9	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , 2020, 77, 761-763.	1.9	51
10	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16641.	3.3	10
11	Reply to Nirmish Singla and Vitaly Margulisâ€™s Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2019.12.018 . The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition. <i>European Urology</i> , 2020, 78, e81-e82.	1.9	2
12	Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy. <i>Gland Surgery</i> , 2020, 9, 495-497.	1.1	1
13	Re: Pathologic Response and Surgical Outcomes in Patients Undergoing Nephrectomy Following Receipt of Immune Checkpoint Inhibitors for Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 288.	1.9	1
14	PLEKHS1: A new molecular marker predicting risk of progression of nonâ€muscleâ€invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	1.8	10
15	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolimmunology</i> , 2019, 8, e1581556.	4.6	68
16	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019, 2, 355-364.	5.4	25
17	Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 144-149.	4.4	13
18	Systemic treatments for high-risk localized prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 498-510.	3.8	36

#	ARTICLE	IF	CITATIONS
19	Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 257-263.	1.6	29
20	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2017, 6, e1358330.	4.6	15
21	Editorial Comment to Different methods of hilar clamping during partial nephrectomy: Impact on renal function. <i>International Journal of Urology</i> , 2014, 21, 237-237.	1.0	0
22	Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 23.e1-23.e8.	1.6	31
23	microRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2013, 132, 2479-2491.	5.1	152
24	Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. <i>European Urology</i> , 2009, 56, 678-689.	1.9	45
25	Survival Analysis of 130 Patients with Papillary Renal Cell Carcinoma: Prognostic Utility of Type 1 and Type 2 Subclassification. <i>Urology</i> , 2007, 69, 230-235.	1.0	211